ReviewNature reviews. Gastroenterology & hepatology2017
Population screening and treatment of Helicobacter pylori infection.
Review in Nature reviews. Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Visceral fat area as a prognostic biomarker in gastric cancer: a systematic review and meta-analysis of survival outcomes.Frontiers in oncology · 2025Pooled it
- Prognostic relevance of platelet lymphocyte ratio (PLR) in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Guideline
- Helicobacter pylori infections in Ethiopia; prevalence and associated factors: a systematic review and meta-analysis.BMC gastroenterology · 2019Pooled it
- The association between red blood cell distribution width-to-albumin ratio andFrontiers in nutrition · 2026Article
- Endogenous and Extracellular Roles of a Tumor Suppressor miR-379-5p in Gastric Cancer.Oncology · 2026Article
- Prevalence of Helicobacter Pylori in Obese Adults: A Literature Review.Physiological research · 2025Review
- Association of dietary fiber intake with Helicobacter pylori infection and all-cause mortality among US population.BMC nutrition · 2025Article
- An pH-responsive liposome for the targeted treatment ofMaterials today. Bio · 2025Article
- Effects of Lactobacillus spp. on Helicobacter pylori: A Promising Frontier in the Era of Antibiotic Resistance.Probiotics and antimicrobial proteins · 2025Review
- Detection ofJournal of imaging · 2025Article
- Antibiotic Resistance and Genetic Determinants ofInternational journal of molecular sciences · 2025Article
- Article
- The Role of Triterpenoids in Gastric Ulcer: Mechanisms and Therapeutic Potentials.International journal of molecular sciences · 2025Review
- Protocol for a randomised 'screen-and-treat'BMJ open · 2025Article
- The first study on population knowledge and attitudes regarding prevention, diagnostic methods, treatment, and recovery aspects related toFrontiers in public health · 2025Article
- Translating evidence into action: overcoming barriers to gastric cancer prevention in Aotearoa.Journal of the Royal Society of New Zealand · 2025Review
- Impact ofDiseases (Basel, Switzerland) · 2024Review
- A nanoparticle-based sonodynamic therapy reduces Helicobacter pylori infection in mouse without disrupting gut microbiota.Nature communications · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori is an important human pathogen, associated with a substantial burden from both malignant and non-malignant diseases. The bacterium is classed as a human carcinogen, being strongly linked with gastric cancer, the third most common cause of cancer death worldwide and is also associated with common conditions such as dyspepsia and peptic ulcer. Eradication of H. pylori reduces the incidence of gastric cancer and peptic ulcer, as well as the prevalence and costs of managing dyspepsia. Economic analyses suggest that eradication of H. pylori as a means of controlling gastric cancer is cost-effective in high-risk populations. Even in populations at low risk of gastric cancer, there might be other benefits arising from screening and treatment, owing to the effects on non-malignant upper gastrointestinal diseases. However, public health authorities have been slow to consider the benefits of population-based screening and treatment as a means of reducing the morbidity and mortality associated with the infection. There are also concerns about widespread use of eradication therapy, including antimicrobial resistance and a rise in the prevalence of diseases that are negatively associated with H. pylori, such as GERD, Barrett oesophagus, asthma and obesity. This Review summarizes these issues.
Indexed as
Identifiers
28053340What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.